Shree Ganesh Remedies Ltd (SGRL)

Loading page…

Shree Ganesh Remedies Ltd (SGRL) · mywealthgrid

About

Shree Ganesh Remedies is a small-cap pharmaceutical company (market cap ₹627.71 Cr) operating in the generic drugs segment. The company demonstrates strong operational efficiency with 36.11% operating margins and maintains a conservative capital structure with debt-to-equity of 0.26.

Face value: ₹10

Market cap

₹889 Cr

P/E

38.5×

P/B

6.1×

Dividend yield

ROE

17.3%

ROCE

20.4%

Debt / equity

0.26

OPM

36.1%

EPS (TTM)

₹18.0

Book value

₹113.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue contracted 49% from ₹26.06 Cr (Mar 2020) to ₹13.26 Cr (Dec 2020), with partial recovery to ₹15.37 Cr (Mar 2021) — verify causes and sustainability since detailed 2026 results unavailable.
Valuation at PE 27.21 appears elevated; stock declined 9.82% over 12 months — verify whether current valuation reflects operational recovery.
Zero FII ownership (0%) and minimal DII (0.52% as of June 2026) create liquidity and analyst-coverage gaps typical for small-cap pharma.
Operating margin volatility from 18% (Mar 2020) to 36.11% (latest) reflects operational sensitivity — verify sustainability of current margin levels.

Generated analysis · source review pending

Growth drivers

Debt-to-equity of 0.26 provides financial flexibility for organic expansion, capex, or acquisitions common in consolidating generic pharma sectors.
Operating margin improved to 36.11% from 18% (Mar 2020), demonstrating cost discipline that generates strong cash flows available for growth investments.
Regular dividend distributions (2021-09-08, 2022-09-15, 2023-09-07) demonstrate stable cash-generation strength with capacity to fund growth if capital allocation shifts.

Generated analysis · source review pending

1,866 historical price candles were omitted because the exchange source has not been verified.

₹694.3+4.3%1Y

Quick read

rule-based

Pros

+Strong return on equity of 20.1% (3-yr avg)
+High return on capital employed of 22.9%
+Healthy operating margin of 36.1%
+Comfortable interest coverage of 15.8×
+High promoter holding of 72.8% with no pledge

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

57/100

Business quality: 77
Valuation: 38

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025
	126	109
COGS	57	36
Gross profit	68	73
	27	34
Operating profit (EBITDA)	42	39
OPM %	33.2%	36.1%
Depreciation	6	10
Interest	1	2
	3	4
Profit before tax	38	31
Tax	10	8
Tax %	26.3%	26.2%
	28	23
PAT margin %	22.3%	21.2%
EPS (₹)	22.3	18
EPS adjusted (₹)	21.9	18
Annual report	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2023	Mar 2024	Mar 2025
Equity capital	13	13	13
Reserves	—	109	132
Minority interest	—	0	—
	—	36	38
	—	13	9
Total equity & liabilities	—	171	192
	58	81	95
CWIP	—	17	8
Investments	—	5	18
	—	69	70
Total assets	—	171	192

₹ Cr	Mar 2024	Mar 2025
	30	31
	-33	-36
	10	-1
Net cash flow	7	-6
Free cash flow	-1	7
CFO / Operating profit %	72.8%	78.2%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: -14%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: -18%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 16%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025
Margins
Gross margin %	54.4%	67%
EBITDA margin %	33.2%	36.1%
EBIT margin %	28.4%	27.3%
PAT margin %	22.3%	21.2%
Working capital
Receivable days	59	75
Inventory days	159	224
Payable days	52	61
NWC days	166	238
Leverage
Current ratio	3.76	4.79
Debt to EBITDA	0.87	0.98
Debt to equity	0.3	0.26
Interest coverage	63.6	15.8
Asset turnover	0.74	0.57
Return ratios
Return on assets %	16.4%	12%
Return on capital employed %	25.5%	20.4%
Return on equity %	23%	15.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	69.33%	69.33%	69.33%	69.35%	70.5%	72.8%	72.8%	72.8%	72.8%	72.8%	72.84%	72.84%
	0%	0%	0%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0%	0%	0%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.52%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	30.67%	30.67%	30.67%	30.64%	29.49%	27.19%	27.19%	27.19%	27.19%	27.2%	27.16%	26.64%
No. of shareholders	—	—	—	—	—	—	—	—	8,752	8,442	8,058	7,822

Promoter holding up 3.51 percentage points since Sep 2023.

Mr. CHANDULAL MANUBHAI KOTHIAExecutive Director-Chairperson-MD
Mr. PARTH CHANDULAL KOTHIAExecutive Director
Mr. MAULIKKUMAR JAYSUKHBHAI SUDANINon-Executive - Independent Director
Ms. PARULBEN SAHANINon-Executive - Independent Director
Ms. SHRUTI RAJESH SOHANENon-Executive - Independent Director
Ms. Hiral Ankitkumar ShahNon - Executive Independent Director
Mr. Aditya Vikrambhai PatelCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	95	0.01	0.01%	0.001%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

24 announcementsExport CSV

12 Sept 2026, 8:44 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

12 Sept 2026, 4:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

21 Aug 2026, 6:55 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

20 Aug 2026, 8:45 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

8 Aug 2026, 12:59 pmBoard Meeting

Board Meeting Intimation for The Unaudited (Standalone And Consolidated) Financial Results Of The Company For The Quarter Ended On June 30, 2026

Exchange filing PDF

17 Jul 2026, 3:57 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Directorate

Change in Directorate PDF

13 Jul 2026, 7:32 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

29 Jun 2026, 9:08 pmCompany Update

Clarification On Price Movement

General PDF

Date	Category	Subject	Filing
12 Sept 2026, 8:44 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
12 Sept 2026, 4:24 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF

Loading announcements…

Shree Ganesh Remedies Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Board and management

Announcements

Annual reports

Investor Presentation and earnings call

Dividends6

Board meetings1

Bonus issues2

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

2